Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727581 | 0.97 | MAPT (0.32) | MAPTKDM4C | |
| SCHEMBL30727594 | 0.90 | MAPT (0.32) | MAPTKDM4C | |
| SCHEMBL30727565 | 0.87 | MAPT (0.32) | MAPTKDM4C | |
| SCHEMBL30727582 | 0.87 | MAPT (0.32) | MAPTKDM4C | |
| SCHEMBL30727629 | 0.84 | MAPT (0.34) | MAPTKDM4C | |
| SCHEMBL30727587 | 0.82 | MAPT (0.34) | MAPTKDM4C | |
| SCHEMBL30727607 | 0.81 | MAPT (0.34) | MAPTKDM4C | |
| SCHEMBL30727623 | 0.80 | ATIC (0.33) | MAPTKDM4C | |
| SCHEMBL30727593 | 0.80 | MAP3K12 (0.33) | MAPTKDM4C | |
| SCHEMBL30727627 | 0.77 | MAPT (0.32) | MAPTKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532495-A1 | CD73 INHIBITOR COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-04-09 | — | — | EP | claimed |
| CN-119585273-A | CD73 inhibitor compounds | 阿道尔克斯治疗有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2023233130-A1 | CD73 INHIBITOR COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2023-12-07 | — | — | WO | claimed |
| EP-4532495-A1 | CD73 INHIBITOR COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-119585273-A | CD73 inhibitor compounds | 阿道尔克斯治疗有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2023233130-A1 | CD73 INHIBITOR COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2023-12-07 | — | — | WO | disclosed |